Company profile: Axenis
1.1 - Company Overview
Company description
- Provider of humanized mouse models as preclinical tools in immunology for the pharmaceutical industry, biotechnology companies, and academic research, using new immunocompromised mouse strains permissive to human tissue xenograft transplantation.
Products and services
🔒
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Axenis
e-Zyvec
HQ: France
Website
- Description: Provider of molecular biology solutions for academic and industrial scientists conducting research with genetic engineering applications; a biotechnology company specializing in genetic engineering, founded in 2016 and headquartered in Loos, France.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full e-Zyvec company profile →
Celmatix
HQ: United States
Website
- Description: Provider of preclinical discovery and development focused on women’s ovarian health, including target identification and validation for endometriosis, PCOS, and ovarian senescence; collaborative discovery, development, and commercialization with Evotec and Bayer; contraceptive target discovery supported by the Bill & Melinda Gates Foundation; and proprietary cohorts, annotations, and NLP-driven research tools.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Celmatix company profile →
Biotheranostics
HQ: United States
Website
- Description: Provider of commercial-stage molecular diagnostics, delivering diagnostic, prognostic, and predictive tests that support physicians in treating cancer, including Breast Cancer Index, a genomic test predicting benefit of extended endocrine therapy in HR+, early-stage breast cancer, and CancerTYPE ID, a gene expression assay identifying tumor type/subtype in metastatic cancer with unknown or unclear diagnoses.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Biotheranostics company profile →
InVivo Biotech Services
HQ: Germany
Website
- Description: Provider of contract manufacturing services for development and production of monoclonal antibodies and recombinant proteins. Offerings include antibody production from hybridomas (small to large scale), recombinant protein expression in bacterial and mammalian systems, non-GMP cell line development, research antibodies produced in HEK under serum-free conditions, and SARS‑CoV‑2 antigens and antibodies for immunoassays.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full InVivo Biotech Services company profile →
Omniome
HQ: United States
Website
- Description: Provider of a proprietary DNA sequencing platform delivering high-accuracy short-read sequencing using Sequencing by Binding (SBB) chemistry. Offers the Onso hardware and software system; validated exome/panel sequencing; single-cell RNA-Seq solutions; and tools for cancer research and gene editing, with lower error rates than traditional sequencing by synthesis.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Omniome company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Axenis
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Axenis
2.2 - Growth funds investing in similar companies to Axenis
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Axenis
4.2 - Public trading comparable groups for Axenis
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →